Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Indiana University
Indiana University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)